Black Diamond Therapeutics (BDTX) closed at $1.81 on November 3, 2026, up 3.4% from the previous close, on volume of 324,850 shares (30-day average 760,665).
Data as of November 3, 2026.
3-Nov-2026
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Wed, 5-Aug 4:01 PM ET)
BDTX Phase 2 Silevertinib Results Update Scheduled—Key Milestone Approaches for EGFRm NSCLC Therapy
Market Chameleon (Wed, 20-May 6:32 AM ET)
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.
As of November 3, 2026, BDTX stock price climbed to $1.81 with 324,850 million shares trading.
BDTX has a beta of 2.35, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.17 to the broad based SPY ETF.
BDTX has a market cap of $103.69 million. This is considered a Micro Cap stock.
Last quarter Black Diamond Therapeutics reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-30 million and exceeded earnings estimates by $.03.
In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.
The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, IWM, FESM, VXF, DFSV.
BDTX has underperformed the market in the last year with a price return of -54.2% while the SPY ETF gained +11.5%. However, in the short term, BDTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +4.3% vs -0.2% return in SPY. But in the last 2 weeks, BDTX shares have been beat by the market, returning -12.6% compared to an SPY return of -1.9%.
BDTX support price is $1.66 and resistance is $1.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.
